Posttransplant lymphoproliferative disorders.
Posttransplant lymphoproliferative disorder is a heterogeneous group of clonal hyperplasia/neoplasms that can range from benign to highly malignant lesions. Mortality rates can approach 60%. This entity has been on the rise for the last 2 decades with the advent of highly potent immunosuppressive agents. Epstein-Barr virus has shown to play a primary role in more than 90% of the cases. Although standard protocols do not exist for primary prevention and treatment, new agents are emerging that may play a role in treatment and prevention of this debilitating, and at times, fatal disease.
Division of Nephrology, Department of Internal Medicine, Saint Louis University School of Medicine, Saint Louis, Missouri 63110, USA.
Asim
A
Chughtai
Bahar
B
Bastani
D020031:Epstein-Barr Virus Infections / Q000276:immunology; D006801:Humans; D007166:Immunosuppressive Agents / Q000009:adverse effects; D008232:Lymphoproliferative Disorders / Q000175:diagnosis / Q000209:etiology* / Q000628:therapy; D012307:Risk Factors; D019737:Transplants / Q000009:adverse effects* / Q000821:virology
D007166:Immunosuppressive Agents